Your browser doesn't support javascript.
loading
Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia
Li, Lijun.
Affiliation
  • Li, Lijun; Jiangxi Maternal and Child Health Hospital. Department of Gynaecology. Nanchang. CN
Rev. Assoc. Med. Bras. (1992, Impr.) ; 69(1): 97-100, Jan. 2023. tab
Article in En | LILACS-Express | LILACS | ID: biblio-1422596
Responsible library: BR1.1
ABSTRACT
SUMMARY

OBJECTIVE:

The aim of this study was to evaluate the clinical efficacy of crisaborole ointment in the treatment of vulvar leukoplakia.

METHODS:

A prospective, randomized controlled clinical trial was conducted, and a total of 100 patients with vulvar leukoplakia were divided into the observation group (n=50) treated with crisaborole ointment and the control group (n=50) treated with vitamin E. The symptom improvement and vulvar leukoplakia score after 2 weeks of treatment were analyzed, and the clinical efficacy of vulvar leukoplakia was evaluated by referring to the Guidelines for Clinical Research of New Drugs of Traditional Chinese Medicine (2018 Edition).

RESULTS:

After 2 weeks of treatment, the overall score of lesions in the observation group decreased, and the total treatment efficiency of patients in the observation group was 92% (46/50), which was significantly higher than that of 52% (26/50) in the control group P<0.05).

CONCLUSION:

Crisaborole ointment can effectively treat vulvar leukoplakia, improving the symptoms and pathological changes of the vulvar skin.
Key words

Full text: 1 Database: LILACS Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Type of study: Clinical_trials / Guideline Language: En Journal: Rev. Assoc. Med. Bras. (1992, Impr.) Year: 2023 Type: Article Affiliation country: China

Full text: 1 Database: LILACS Traditional Medicines: Medicinas_tradicionales_de_asia / Medicina_china Type of study: Clinical_trials / Guideline Language: En Journal: Rev. Assoc. Med. Bras. (1992, Impr.) Year: 2023 Type: Article Affiliation country: China